Page 4 - Tsrl Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tsrl inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tsrl Inc Today - Breaking & Trending Today
Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+ from Treatment with Lynparza More Than 20,000 Patients in Japan Now Qualify for Genetic Testing SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis ® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japans Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect. ....
Font : A-A+ SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. Myriads myChoice test is the only one of its kind to be approved for reimbursement in Japan, said Nicole Lambert, president of Myriad Genetic Laboratories. This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer. ....
Posted January 8th, 2021 for Myriad SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.” ....